Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$5.5B
193M shares
52-week range
$16.24 – $45.30
43% from low
Exchange
NASDAQ
ADRC
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.1M | $61.8M | $75.0M | $68.8M | $117.0M | $285.1M | $627.2M | $1.03B |
| Cost of revenue | $0 | $0 | $0 | $0 | $65.4M | $144.2M | $234.6M | $408.1M |
| Gross profit | $49.1M | $61.8M | $75.0M | $68.8M | $51.6M | $140.9M | $392.7M | $620.8M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 44.1% | 49.4% | 62.6% | 60.3% |
| R&D | $60.6M | $161.9M | $232.2M | $313.3M | $335.6M | $382.2M | $413.5M | $414.7M |
| Operating income | −$1.5M | −$132.5M | $0 | −$392.3M | −$455.6M | −$439.5M | −$303.2M | −$136.5M |
| EBITDA | $149.0K | −$129.4M | −$298.2M | −$392.4M | −$416.5M | −$477.9M | −$113.2M | −$232.3M |
| Net income | −$2.8M | −$101.6M | −$266.4M | −$403.6M | −$446.3M | −$518.3M | −$177.0M | −$296.8M |
| Net margin | -5.7% | -164.4% | -355.2% | -586.4% | -381.5% | -181.8% | -28.2% | -28.8% |
| EPS (diluted) | -0.03 | -1.01 | -2.57 | -2.74 | -2.81 | -2.94 | -0.97 | -1.60 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.4B | $0.03 | $-0.35–$0.19 | 3 |
| 2027 | $1.8B | $0.82 | $0.19–$1.17 | 4 |
| 2028 | $2.1B | $1.39 | $1.05–$1.72 | 2 |
| 2029 | $2.4B | $1.36 | $1.18–$1.52 | 1 |
Forward consensus · source: Financial Modeling Prep
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
www.legendbiotech.comNo one on the platform currently holds LEGN.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 521,800 | $9.4M |
| Bridgewater Associatesas of 2025-03-31 | 225,449 | $7.6M |
No one on the platform has traded LEGN yet.
| $6.3B |
| — |
| IDYAIDEAYA Biosciences, Inc. | $36.74 | +1.24% | $3.5B | — |
| IRONDisc Medicine, Inc. | $74.78 | +6.58% | $2.9B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$SLS $ALT $TNXP spread the word @BioRich sadly does not know what he is doing. These three have been hidden gems in plain sight 💎 💎 💎 💎 SLS may be peaking out soon. But ALT, IMRX, and TNXP could each 3-10x quickly 🤫 GHCA - Global Health Care Academy 🏫 Will be open soon. We will expose fraudsters of all time, sharing incredible stocks to buy, and i will share my favorite targets to short. $LEGN may be my top short selling target the next 6 months. 😈 China and Europe are robbing the US pharmaceutical sector BLIND! Where is @PresidentTrump2025 when we need him?
View on StockTwits ↗$LEGN simple mathematic, conservative carvykti sales of 1.5b and np of 150b, PE 20 means 3 billion, valuation for LB2501, LB2503 and LB2505 of 1b each, total = 6b..so now is not expensive
View on StockTwits ↗$LEGN I feel the odds of LEGN getting bought are about 80% be November data drop the data is too promising plus BOD moves by LEGN and restructuring by JNJ mean the stars are aligned.
View on StockTwits ↗$LEGN JJ selling orthopedics unit, pretty strange after said yesterday mRNA coming to clinic with their own invivo car t. I think it’s starting to bubble
View on StockTwits ↗$LEGN did offering close yet? what's the money for? I thought they are profitable now
View on StockTwits ↗$SOUN wouldn’t worry about them only 3 months ago was in $LEGN at $17.02 they was sell sell sell I was buy buy buy l sold at $30.87 same as this now
View on StockTwits ↗$LUNR hmmm if this gets to $17 or even below $18 I thinks it’s a heck of deal for a swing up Such a good company Just pains me as I’d need to sell some $LEGN or $RXRX Tough decision but I do love LUNR and this feels like an entry opportunity when it finds its bottom
View on StockTwits ↗$LEGN nothing new, just additional info on underwriters https://www.wsgr.com/en/insights/firm-advises-underwriters-on-legend-biotechs-public-offering.html#:~:text=In%20addition%2C%20Legend%20Biotech%20has%20granted%20the,the%20underwriters'%20option%20to%20purchase%20additional%20ADSs.
View on StockTwits ↗$LEGN Probably a good time to buy now. Glad I got the chance to get some more.
View on StockTwits ↗$LEGN hopefully once the selling pressure is done with the public offering closing we can start the grind back up to $50+. We have a nice tailwind with the xbi at the moment which should help
View on StockTwits ↗$LEGN Hopefully the follow on offering closed today. The today’s closing price matches the offering price. Let’s wait for next catalyst. Hopefully they will share the (good) data publicly first and let the street decide.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 7.2× sales vs its 38.2× historical median P/S.
Fair value ≈ $152.23 · price $28.71 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.